Wednesday, July 8, 2026

Patent intelligence · US

US 12194065

Methods and compositions to enhance metabolic detoxification systems

granted A61KA61K2035/115A61K31/194A61K31/198
Status granted
Linked drugs 3
Pipeline programs 6
Years to expiry 19
Applicant portfolio 121
Patent details — US 12194065
Jurisdiction
US
Status
granted
Grant date
Jan 14, 2025
Expiration
Jan 9, 2045
Claims
18
CPC classes
A61K, A61K2035/115, A61K31/194, A61K31/198
View on Google Patents ↗

Quick answer

US 12194065 (Methods and compositions to enhance metabolic detoxification systems) is held by Nature's Sunshine Products, Inc.. Status: granted. Granted Jan 14, 2025. Expires Jan 9, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
18
CPC classes
A61K, A61K2035/115, A61K31/194, A61K31/198, A61K31/375, A61K31/409

More from Nature's Sunshine Products, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12428432

    Thienopyrimidine derivatives having stereo configurations and use thereof in medicine

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  2. US 12428389

    Diarylamide compound and application thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Sep 25, 2045

    granted
  3. US 12384853

    Anti-HER2/PD1 bispecific antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Aug 7, 2045

    granted
  4. US 12324812

    Glucopyranosyl derivatives and their uses

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Jun 5, 2045

    granted
  5. US 12319748

    Antibody binding to human HER2 and preparation method and use thereof

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires May 29, 2045

    granted
  6. US 12312348

    RET inhibitors, pharmaceutical compositions and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires May 22, 2045

    granted
  7. US 12269886

    Tetravalent bispecific antibody against PD-1 and PD-L1

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Expires Apr 3, 2045

    granted
  8. US 12258317

    Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Expires Mar 20, 2045

    granted

Frequently asked questions

What is US patent 12194065?

US 12194065 (Methods and compositions to enhance metabolic detoxification systems) is held by Nature's Sunshine Products, Inc.. Status: granted. Granted Jan 14, 2025. Expires Jan 9, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12194065?

Nature's Sunshine Products, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.

When does US 12194065 expire?

Our index shows an expiration date of Jan 9, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.